Neogen Corporation (NEOG) Operating Margin
- Operating margin · 12 months: Value -2.48%; Formula and calculation Operating income / revenue. Period ending 2026-05-31..
Operating margin
Overview →Financial period ending 2026-05-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -2.48% | Operating income / revenue. Period ending 2026-05-31. $-21.60M ÷ $870.40M × 100 ≈ -2.48% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -21.60M USD | Operating Income (Loss) |
| Revenue | 870.40M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 461.90M USD | Cost of Goods and Services Sold |
| Research and development | 18.40M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-05-31 | $-21.60M | $870.40M | $461.90M | $18.40M | (m) | -2.48% |
| 2026-02-28 | $-635.90M | $870.56M | $476.99M | $19.79M | (m) | -73.04% |
| 2025-11-30 | $-627.24M | $880.32M | $475.55M | $20.47M | (m) | -71.25% |
| 2025-08-31 | $-1.08B | $886.89M | $475.47M | $21.01M | (m) | -121.70% |
| 2025-05-31 | $-1.06B | $894.66M | $473.29M | $21.09M | (m) | -118.59% |
| 2025-02-28 | $-436.77M | $906.00M | $463.99M | $19.93M | (m) | -48.21% |
| 2024-11-30 | $-430.16M | $913.83M | $465.21M | $20.30M | (m) | -47.07% |
| 2024-08-31 | $41.78M | $912.20M | $460.13M | $20.95M | (m) | 4.58% |
| 2024-05-31 | $58.66M | $924.22M | $460.32M | $22.48M | (m) | 6.35% |
| 2024-02-29 | $69.05M | $929.24M | $455.64M | $24.39M | (m) | 7.43% |
| 2023-11-30 | $72.71M | $918.68M | $454.00M | $26.79M | (m) | 7.91% |
| 2023-08-31 | $50.59M | $919.09M | $458.64M | $27.88M | (m) | 5.50% |
| 2023-05-31 | $37.52M | $822.45M | $416.49M | $26.04M | (m) | 4.56% |
| 2023-02-28 | $32.12M | $720.73M | $372.96M | $22.82M | (m) | 4.46% |
| 2022-11-30 | $22.81M | $630.72M | $333.50M | $20.12M | (m) | 3.62% |
| 2022-08-31 | $42.94M | $531.20M | $285.93M | $17.61M | (m) | 8.08% |
| 2022-05-31 | $58.62M | $527.16M | $284.15M | $17.05M | (m) | 11.12% |
| 2022-02-28 | $60.85M | $514.49M | $278.79M | $17.30M | (m) | 11.83% |
| 2021-11-30 | $70.24M | $502.96M | $270.81M | $16.97M | (m) | 13.97% |
| 2021-08-31 | $77.02M | $487.44M | $262.68M | $16.69M | (m) | 15.80% |
| 2021-05-31 | $74.17M | $468.46M | $253.40M | $16.25M | (m) | 15.83% |
| 2021-02-28 | $73.86M | $450.11M | $241.01M | $15.63M | (m) | 16.41% |
| 2020-11-30 | $71.13M | $433.27M | $232.69M | $15.21M | (m) | 16.42% |
| 2020-08-31 | $70.15M | $426.07M | $227.68M | $14.94M | (m) | 16.47% |
| 2020-05-31 | $67.52M | $418.17M | $221.89M | $14.75M | (m) | 16.15% |
| 2020-02-29 | $66.31M | $418.86M | $223.78M | $14.86M | (m) | 15.83% |
| 2019-11-30 | $67.91M | $416.69M | $222.31M | $14.29M | (m) | 16.30% |
| 2019-08-31 | $67.88M | $415.98M | $222.60M | $13.67M | (m) | 16.32% |
| 2019-05-31 | $68.09M | $414.19M | $222.27M | $12.80M | (m) | 16.44% |
| 2019-02-28 | $69.22M | $412.54M | $222.66M | $11.19M | (m) | 16.78% |
| 2018-11-30 | $70.50M | $409.75M | $219.89M | $10.78M | (m) | 17.21% |
| 2018-08-31 | $70.25M | $403.33M | $215.27M | $10.58M | (m) | 17.42% |
| 2018-05-31 | $70.19M | $402.25M | $212.00M | $10.86M | (m) | 17.45% |
| 2018-02-28 | $69.33M | $391.81M | (m) | $11.20M | (m) | 17.70% |
| 2017-11-30 | $67.77M | $384.31M | (m) | $11.00M | (m) | 17.64% |
| 2017-08-31 | $66.63M | $373.20M | (m) | $10.80M | (m) | 17.85% |
| 2017-05-31 | $64.94M | $361.59M | (m) | $10.38M | (m) | 17.96% |
| 2017-02-28 | $61.57M | $352.83M | (m) | $10.34M | (m) | 17.45% |
| 2016-11-30 | $58.47M | $341.17M | (m) | $10.14M | (m) | 17.14% |
| 2016-08-31 | $56.23M | $330.06M | (m) | $9.99M | (m) | 17.04% |
| 2016-05-31 | $56.39M | $321.27M | (m) | $9.89M | (m) | 17.55% |
| 2016-02-29 | $55.38M | $309.81M | (m) | $9.97M | (m) | 17.88% |
| 2015-11-30 | $56.29M | $301.49M | (m) | $9.89M | (m) | 18.67% |
| 2015-08-31 | $54.57M | $290.33M | (m) | $9.75M | (m) | 18.80% |
| 2015-05-31 | $53.12M | $283.07M | (m) | $9.58M | (m) | 18.76% |
| 2015-02-28 | $49.49M | $271.73M | (m) | $9.07M | (m) | 18.21% |
| 2014-11-30 | $47.62M | $265.31M | (m) | $8.81M | (m) | 17.95% |
| 2014-08-31 | $44.41M | $256.46M | (m) | $8.64M | (m) | 17.32% |
| 2014-05-31 | $43.39M | $247.41M | (m) | $8.33M | (m) | 17.54% |
| 2014-02-28 | $42.64M | $236.15M | (m) | $8.38M | (m) | 18.05% |
| 2013-11-30 | $42.01M | $225.21M | (m) | $8.25M | (m) | 18.65% |
| 2013-08-31 | $42.80M | $216.35M | (m) | $7.94M | (m) | 19.78% |
| 2013-05-31 | $40.71M | $207.53M | (m) | $7.78M | (m) | 19.61% |
| 2013-02-28 | $39.17M | $200.07M | (m) | $7.56M | (m) | 19.58% |
| 2012-11-30 | $37.05M | $193.93M | (m) | $7.33M | (m) | 19.11% |
| 2012-08-31 | $34.72M | $188.08M | (m) | $7.05M | (m) | 18.46% |
| 2012-05-31 | $33.74M | $184.05M | (m) | $6.64M | (m) | 18.33% |
| 2012-02-29 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-11-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-08-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-05-31 | $35.84M | $172.68M | (m) | $6.83M | (m) | 20.75% |
| 2011-02-28 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-11-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-08-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-05-31 | $26.88M | $140.51M | (m) | $6.26M | (m) | 19.13% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |